RapidVector™ Services: Small-Scale Studies To Support Preclinical Viral Vector Development

Committing to large-scale manufacturing before a viral vector construct has been evaluated is a costly way to find problems. RapidVector™ Services offer an earlier checkpoint for AAV and LV programs, built on more than 30 years of vector development and manufacturing experience. Two study tiers match the next milestone: a 4L proof-of-concept batch for feasibility, and a 10L LV or 15L AAV preclinical batch for IND-enabling work such as tox studies, analytical method development, reference standard generation, and starting stability studies. Each includes a pre-defined analytical panel, all-in pricing, and timelines backed by a guarantee (under 8 weeks for feasibility, under 12 for IND-enabling). Timelines exclude GOI plasmid production.

Explore the options to see which fits your program's next step.